Ginkgo biloba extract and ginkgolide antiarrhythmic potential by targeting hERG and ICa-L channel

Journal of Pharmacological Sciences

Volumn 123, Issue 4, 2013, Pages 318-327

  Zhao, Xin ^a   Yao, Hong ^a   Yin, Hao Lan ^a   Zhu, Qi Lei ^a   Sun, Jia Liang ^a   Ma, Wei ^a   Shi, Yuan Qi ^a   Liang, Zhao Guang ^a   Li, Bao Xin ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Key Lab of Biopharmaceut Eng   (China)

Author keywords

Action potential duration (APD); Ginkgo biloba extract (GBE); Ginkgolide (GLD); Human ether a go go related gene (hERG) potassium channel

Indexed keywords

CALCIUM CHANNEL L TYPE; GINKGO BILOBA EXTRACT; GINKGOLIDE; POTASSIUM CHANNEL HERG;

ACTION POTENTIAL; ANIMAL CELL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; GUINEA PIG; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE MUSCLE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MOLECULAR IMAGING; NONHUMAN; PROTEIN TARGETING; WHOLE CELL PATCH CLAMP;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CALCIUM; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; GINKGO BILOBA; GINKGOLIDES; GUINEA PIGS; HEART VENTRICLES; HEK293 CELLS; HUMANS; MOLECULAR TARGETED THERAPY; MYOCYTES, CARDIAC; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84892640106     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13118FP     Document Type: Article

References (30)

1. Chen JW, Chen YH, Lin FY, Chen YL, Lin SJ. Ginkgo biloba extract inhibits tumor necrosis factor-alpha-induced reactive oxygen species generation, transcription factor activation, and cell adhesion molecule expression in human aortic endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:1559-1566.
2. Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJ. Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma. J Korean Ophthalmol Soc. 2011;25:323-328.
3. Janssens D, Michiels C, Delative E, Eliaers F, Drieu K, Remacle J. Protection of hypoxia-induced ATP decrease in endothelial cells by Ginkgo biloba extract and bilobalide. Biochem Pharmacol. 1995;50:991-999.
4. DeFeudis FV. Ginkgo biloba Extract (EGB 761): pharmacological activities and clinical applications. In: DeFeudis FV, editors. Clinical studies and clinical pharmacology with Egb. 761. Paris: Elsevier; 1991. p. 97-142.
5. Klein J, Chatterjee SS, Loffelholz K. Phospholipid breakdown and choline release under hypoxic conditions:inhibition by bilobalide, a con-situent of Ginkgo biloba. Brain Res. 1997;755:347-350.
6. Rioufol G, Pietri S, Culcasi M, Loufoua J, Staat P, Pop C, et al. Ginkgo biloba extract EGb 761 attenuates myocardial stunning in the pig heart. Basic Res Cardiol. 2003 Feb;98:59-68.
7. Schoilcher H. Ginkgo biloba L. Untersuchung zur Qualitat, Wirkung, Wirksamkeit und Unbedenkichkeit. Zeitschr Phytother. 1988;9:119-127. (text in German)
8. Pietri S, Séguin JR, d'Arbigny P, Drieu K, Culcasi M. Ginkgo biloba extract (EGb 761) pretreatment limits free radical-induced oxidative stress in patients undergoing coronary bypass surgery. Cardiovasc Drugs Ther. 1997;11:121-131.
9. Kampkotter A, Pielarski T, Rohrig R, Timpel C, Chovolou Y, Watjen W, et al. The Ginkgo biloba extract EGb761 reduces stress sensitivity,ROS accumulation and expression of catalase and glutathione S-transferase 4 in Caenorhabditis elegans. Pharmacol Res. 2007;55:139-147.
10. Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, Hill AP. hERG K(+) channels: structure, function, and clinical significance. Physiol Rev. 2012;92:1393-1478.
11. Tsujimae K, Suzuki S, Yamada M, Kurachi Y. Comparison of kinetic properties of quinidine and dofetilide block of hERG channels. Eur J Pharmacol. 2004;493:29-40.
12. Li BX, Yang BF, Zhou J, Xu CQ, Li YR. Inhibitory effects of berberine on Ik1, Ik, and hERG channels of cardiac myocytes. Acta Pharmacol Sin. 2001;22:125-131.
13. Zhao WX, Qi ZP, Bai YL, Zhang Y, Zhao XL, Lu YJ, et al. Effect of resveratrol on function of hERG K+ channels. Chin Pharmacol Bull. 2007;23:865-869.
14. Farkas AS, Nattel S. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice. Drugs. 2010;70:573-603.
15. Hong HK, Park MH, Lee BH, Jo SH. Block of the human ether-a-go-gorelated gene (hERG) K+ channel by the antidepressant desipramine. Biochem Biophys Res Commun. 2010;394:536-541.
16. Schramm A, Baburin I, Hering S, Hamburger M. hERG channel inhibitors in extracts of coptidis rhizoma. Planta Med. 2011;77:692-697.
17. Varga E, Bodi A, Ferdinandy P, Droy-Lefaix MT, Blasig IE, Tosaki A. The protective effect of EGb 761 in isolated ischemic/reperfused rat hearts:a link between cardiac function and nitric oxide production. J Cardiovasc Pharmacol. 1999,34:711-717.
18. Zhang Y, Liu Y, Wang T, Li B, Li H, Wang Z, et al. Resveratrol, a natural ingredient of grape skin: Antiarrhythmic efficacy and ionic mechanisms. Biochem Biophys Res Commun. 2006;340:1192-1199.
19. Yang B, Lin H, Xu C, Liu Y, Wang H, Han H, et al. Choline produces cytoprotective effects against ischemic myocardial injuries: evidence for the role of cardiac M3 subtype muscarinic acetylcholine Receptors. Cell Physio Biochem. 2005;16:163-174.
20. Du X, Lu D, Daharsh ED, Yao A, Dewoody R, Yao J-A. Dimethy sulfoxide effects on hERG channels expressed in hek293 cells. J Pharmacol Toxicol Methods. 2006;54:164-172.
21. Gu DF, Li XL, Qi ZP, Shi SS, Hu MQ, Liu DM, et al. Blockade of hERG K+ channel by isoquinoline alkaloid neferine in the stable transfected HEK293 cells. Naunyn Schmiedebergs Arch Pharmacol. 2009;380:143-151.
22. Chu WF, Sun HL, Dong DL, Qiao GF, Yang BF. Increasing intracellular calcium of guinea pig ventricular myocytes induced by platelet activating factor through IP3 pathway. Basic Clin Pharmacol Toxicol. 2006;98:104-109.
23. Kr activation in a cellular model of LQT3. Heart Rhythm. 2009;6:100-106.
24. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440:463-469.
25. Zitron E, Kiesecker C, Scholz E, Luck S, Bloehs R, Kathofer S, et al. Inhibition of cardiac hERG potassium channels by the atypical antidepressant trazodone. N-S Arch Pharmacol. 2004;370:146-156.
26. Zitron E, Karle CA, Wendt-Nordahl G, Kathofer S, Zhang W, Thomas D, et al. Bertosamil blocks hERG potassium channels in their open and inactivated states. Br J Pharmacol. 2002;137:221-228.
27. Karle CA, Kreye VA, Thomas D, Rockl K, Kathofer S, Zhang W, et al. Antiarrhythmic drug carvedilol inhibits hERG potassium channels. Cardiovasc Res. 2001;49:361-370.
28. Koltai M, Tosaki A, Hosford D, Braquet P. Ginkgolide B protects isolated hearts against arrhythmias induced by ischemia but not reperfusion. Eur J Pharmacol. 1989;164:293-302.
29. Kiehn J, Thomas D, Karle CA, Schols W, Kubler W. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned hERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:212-219.
30. Zhang YH, Cheng H, Alexeenko VA, Dempsey CE, Hancox JC. Characterization of recombinant hERG K(+) channel inhibition by the active metabolite of amiodarone desethyl-amiodarone. J Electrocardiol. 2010;43:440-448.